ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
-9.67%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$53.8M
AUM Growth
+$53.8M
(-6.5%)
Cap. Flow
+$1.7M
Cap. Flow
% of AUM
3.16%
Top 10 Holdings %
Top 10 Hldgs %
73.8%
Holding
26
New
6
Increased
8
Reduced
6
Closed
6
Top Buys
| 1 |
HMSY
HMS Holdings Corp.
HMSY
|
$4.81M |
| 2 |
Quest Diagnostics
DGX
|
$2.28M |
| 3 |
Eli Lilly
LLY
|
$1.76M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$1.57M |
| 5 |
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
|
$1.32M |
Top Sells
| 1 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$3.28M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
$2.25M |
| 3 |
UnitedHealth
UNH
|
$1.93M |
| 4 |
Neurocrine Biosciences
NBIX
|
$1.91M |
| 5 |
Incyte
INCY
|
$1.71M |
Sector Composition
| 1 | Healthcare | 82.46% |
| 2 | Industrials | 8.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
PTC Therapeutics
PTCT
$3.92B
| $5.29M | 9.83% | 484,579 -83,104 | -15% | -$907K |
|
2
Centene
CNC
$14.3B
| $5.06M | 9.41% | 89,569 +21,713 | +32% | +$1.23M |
|
|
HMSY
3
DELISTED
HMS Holdings Corp.
HMSY
| $4.81M | 8.94% | +264,760 | New | +$4.81M |
|
|
4
Jazz Pharmaceuticals
JAZZ
$7.75B
| $4.64M | 8.64% | 42,597 +14,368 | +51% | +$1.57M |
|
|
5
Eli Lilly
LLY
$657B
| $4.19M | 7.79% | 56,984 +23,955 | +73% | +$1.76M |
|
6
Amicus Therapeutics
FOLD
$2.34B
| $3.76M | 6.99% | 756,596 +138,279 | +22% | +$687K |
|
|
SGYP
7
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $3.38M | 6.28% | 555,085 +216,017 | +64% | +$1.32M |
|
|
8
Bio-Rad Laboratories Class A
BIO
$8.06B
| $3.34M | 6.21% | 18,318 -12,369 | -40% | -$2.25M |
|
|
9
Quest Diagnostics
DGX
$20.3B
| $2.71M | 5.04% | 29,485 +24,785 | +527% | +$2.28M |
|
|
10
UnitedHealth
UNH
$281B
| $2.51M | 4.66% | 15,659 -12,069 | -44% | -$1.93M |
|
|
AERI
11
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $2.43M | 4.51% | 64,095 -86,556 | -57% | -$3.28M |
|
|
IPXL
12
DELISTED
Impax Laboratories, Inc.
IPXL
| $2.2M | 4.09% | 166,099 +1,943 | +1% | +$25.7K |
|
|
NVRO
13
DELISTED
NEVRO CORP.
NVRO
| $2.09M | 3.88% | 28,725 +16,564 | +136% | +$1.2M |
|
|
14
Incyte
INCY
$16.5B
| $2.04M | 3.79% | 20,337 -17,070 | -46% | -$1.71M |
|
15
DaVita
DVA
$9.85B
| $1.25M | 2.32% | +19,451 | New | +$1.25M |
|
16
Edwards Lifesciences
EW
$47.8B
| $956K | 1.78% | 10,200 -3,708 | -27% | -$348K |
|
17
Ironwood Pharmaceuticals
IRWD
$214M
| $877K | 1.63% | +57,363 | New | +$877K |
|
18
Perrigo
PRGO
$3.27B
| $861K | 1.6% | +10,339 | New | +$861K |
|
|
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
| $703K | 1.31% | +15,832 | New | +$703K |
|
20
Natera
NTRA
$23.1B
| $694K | 1.29% | +59,300 | New | +$694K |
|
21
Glaukos
GKOS
$5.5B
| – | – | -10,233 | Closed | -$386K |
|
22
Galapagos
GLPG
$2.07B
| – | – | -6,250 | Closed | -$404K |
|
|
23
Neurocrine Biosciences
NBIX
$13.8B
| – | – | -37,644 | Closed | -$1.91M |
|
24
NovoCure
NVCR
$1.38B
| – | – | -157,176 | Closed | -$1.34M |
|